Pharming Group N.V.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHGUF research report →
Companywww.pharming.com
Pharming Group N. V. , a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally.
- CEO
- Fabrice Chouraqui
- IPO
- 2002
- Employees
- 404
- HQ
- Leiden, NL
Price Chart
Valuation
- Market Cap
- $904.00M
- P/E
- 76.85
- P/S
- 2.47
- P/B
- 3.56
- EV/EBITDA
- 28.86
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 88.12%
- Op Margin
- 6.36%
- Net Margin
- 3.37%
- ROE
- 4.75%
- ROIC
- 3.76%
Growth & Income
- Revenue
- $391.32M · 31.67%
- Net Income
- $2.97M · 126.17%
- EPS
- $0.00 · 124.26%
- Op Income
- $20.09M
- FCF YoY
- 860.99%
Performance & Tape
- 52W High
- $2.17
- 52W Low
- $1.00
- 50D MA
- $1.54
- 200D MA
- $1.57
- Beta
- 0.12
- Avg Volume
- 845
Get TickerSpark's AI analysis on PHGUF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PHGUF Coverage
We haven't published any research on PHGUF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHGUF Report →